Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15033139 | 0.94 | LRRK2 (0.88) | LRRK2TTK | |
| SCHEMBL7454471 | 0.92 | LRRK2 (1.00) | LRRK2TTK | |
| SCHEMBL7449691 | 0.90 | LRRK2 (1.00) | LRRK2TTK | |
| SCHEMBL7453585 | 0.89 | LRRK2 (1.00) | LRRK2TTK | |
| SCHEMBL7449799 | 0.89 | LRRK2 (1.00) | LRRK2TTK | |
| SCHEMBL7450006 | 0.89 | LRRK2 (1.00) | LRRK2TTK | |
| SCHEMBL14994503 | 0.88 | LRRK2 (0.82) | LRRK2TTK | |
| SCHEMBL15003190 | 0.88 | LRRK2 (0.89) | LRRK2TTK | |
| SCHEMBL7515829 | 0.88 | LRRK2 (1.00) | LRRK2TTK | |
| SCHEMBL14995464 | 0.87 | LRRK2 (0.94) | LRRK2TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3075730-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2016-10-05 | — | — | EP | claimed |
| EP-2785381-B1 | FLUORINE-18 AND CARBON-11 LABELED RADIOLIGANDS FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING FOR LRRK2 | HOFFMANN LA ROCHE (CH) | 2016-05-18 | — | — | EP | claimed |
| EP-2576541-B1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | HOFFMANN LA ROCHE (CH) | 2016-04-06 | — | — | EP | claimed |
| US-9139566-B2 | Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (PET) imaging for LRRK2 | GENENTECH, INC. (US) | 2015-09-22 | — | — | US | claimed |
| EP-2785381-A1 | FLUORINE-18 AND CARBON-11 LABELED RADIOLIGANDS FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING FOR LRRK2 | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-08 | — | — | EP | claimed |
| US-20130156700-A1 | FLUORINE-18 AND CARBON-11 LABELED RADIOLIGANDS FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING FOR LRRK2 | GENENTECH, INC. (US) | 2013-06-20 | — | — | US | claimed |
| WO-2013079496-A1 | FLUORINE-18 AND CARBON-11 LABELED RADIOLIGANDS FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING FOR LRRK2 | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-06 | — | — | WO | claimed |
| US-8354420-B2 | Aminopyrimidine derivatives as LRRK2 inhibitors | GENENTECH, INC. (US) | 2013-01-15 | — | — | US | claimed |
| EP-3075730-B1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2018-10-24 | — | — | EP | disclosed |
| EP-3075730-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2016-10-05 | — | — | EP | disclosed |
| EP-3075730-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2016-10-05 | — | — | EP | disclosed |
| EP-2785381-B1 | FLUORINE-18 AND CARBON-11 LABELED RADIOLIGANDS FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING FOR LRRK2 | HOFFMANN LA ROCHE (CH) | 2016-05-18 | — | — | EP | disclosed |
| EP-2785381-B1 | FLUORINE-18 AND CARBON-11 LABELED RADIOLIGANDS FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING FOR LRRK2 | HOFFMANN LA ROCHE (CH) | 2016-05-18 | — | — | EP | disclosed |
| EP-2576541-B1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | HOFFMANN LA ROCHE (CH) | 2016-04-06 | — | — | EP | disclosed |
| US-8354420-B2 | Aminopyrimidine derivatives as LRRK2 inhibitors | GENENTECH, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20110301141-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 INHIBITORS | GENENTECH, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301141-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 INHIBITORS | GENENTECH, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301141-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 INHIBITORS | GENENTECH, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2011151360-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011151360-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130156700-A1 | FLUORINE-18 AND CARBON-11 LABELED RADIOLIGANDS FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING FOR LRRK2 | LRRK2, PARK7, SLC18A2 | LRRK2 1/4885TTK 2948/4885 |
| US-20110301141-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 INHIBITORS | LRRK2, PARK7, PKN2 | LRRK2 1/4885TTK 3237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.